Program
Lamivudine
Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.
Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 352 open or running | phase 4since Feb 15, 2000 | Nov 2, 1999 | Sep 14, 2032phase 3 · NCT07393659 |
| Bristol-Myers Squibbits history only | 70 open or running | phase 4since Jun 27, 2005 | Nov 2, 1999 | none ahead |
| Abbottits history only | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Dupont Merckits history only | 20 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| triangle-pharmaceuticalsits history only | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Nov 2, 1999.
- Jun 13, 2012Phase 3 study in HIVBristol-Myers Squibb · NCT01620944 · 3 enrolled
- Jul 25, 2013Phase 3 study in InfectionsGlaxoSmithKline · NCT01910402 · 499 enrolled · United States, Argentina, Canada and more
- Apr 3, 2014Phase 3 study in InfectionsGlaxoSmithKline · NCT02105987 · 555 enrolled · United States, Canada, Puerto Rico
- Dec 14, 2015Phase 4 study in InfectionsGlaxoSmithKline · NCT02634073 · 16 enrolled · United States
- Apr 11, 2016Phase 1 study in InfectionsGlaxoSmithKline · NCT02738931 · 30 enrolled · United States
- Jul 8, 20162 phase 3 studies in InfectionsGlaxoSmithKline · NCT02831764, NCT02831673
- Mar 8, 2017Phase 1 study in InfectionsGlaxoSmithKline · NCT03078556 · 154 enrolled · United States
- Jan 5, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03446573 · 743 enrolled · United States, Australia, Belgium and more
- Sep 21, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
- May 8, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03945981 · 131 enrolled · United States
- Jul 11, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
- Jun 9, 20232 phase 3 studies in HIV InfectionsGlaxoSmithKline · NCT05911360, NCT05917509
- Jul 19, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
- Jan 30, 2026Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | GlaxoSmithKline | Sep 14, 2032 | 197 |
| NCT05979311HIV Infections · Argentina, Belgium, Denmark and more | 3 | Active, not recruiting | GlaxoSmithKline | Apr 15, 2026 | 463 |
| NCT05917509HIV Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 16, 2025 | 171 |
| NCT05911360HIV Infections · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 23, 2026 | 205 |
| NCT04021290HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 23, 2021 | 493 |
| NCT03945981HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Apr 29, 2020 | 131 |
| NCT03682848HIV Infections · Kenya, South Africa, Thailand | 3 | Completed | GlaxoSmithKline | Dec 1, 2021 | 32 |
| NCT03446573HIV Infections · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | May 20, 2019 | 743 |
| NCT03078556Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 18, 2017 | 154 |
| NCT02831764Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 4, 2018 | 722 |
| NCT02831673Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Mar 29, 2018 | 719 |
| NCT02738931Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2016 | 30 |
| NCT02634073Infections · United States | 4 | Completed | GlaxoSmithKline | Mar 1, 2016 | 16 |
| NCT02105987Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | Apr 2015 | 555 |
| NCT01910402Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 22, 2015 | 499 |
| NCT01620944HIV | 3 | Terminated | Bristol-Myers Squibb | Jan 22, 2013 | 3 |
| NCT00549198Infections · Austria, Belgium, Denmark and more | 4 | Completed | GlaxoSmithKline | Dec 2009 | 392 |
| NCT00440947Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | Jul 2010 | 515 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2011 | 629 |
| NCT00354653Hepatitis B, Chronic · Iran, Islamic Republic of | 4 | Completed | GlaxoSmithKline | Jan 23, 2007 | 100 |
| NCT00337922HIV Infections · Japan | 4 | Completed | GlaxoSmithKline | 8 | |
| NCT00234923HIV Infections | 3 | Completed | Abbott | Feb 2007 | 138 |
| NCT00140725Hepatitis B, Chronic · Hong Kong | 3 | Completed | GlaxoSmithKline | 160 | |
| NCT00135369HIV Infections · United States, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | Jul 2005 | 300 |
| NCT00116298HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Jan 2005 | 900 |
| NCT00116116HIV Infections · United States | 4 | Completed | Bristol-Myers Squibb | Jun 2005 | 70 |
| NCT00085943HIV Infections · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | 866 | |
| NCT00046176Infections · United States, Costa Rica, Panama and more | 3 | Completed | GlaxoSmithKline | May 17, 2004 | 240 |
| NCT00043953HIV Infections · United States, Canada | 2 | Completed | Abbott | 30 | |
| NCT00038220HIV Infections · United States | 2 | Completed | Abbott | 40 | |
| NCT00013897HIV Infections · United States, Austria, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Apr 2003 | |
| NCT00011895HIV Infections · United States | 4 | UNKNOWN | GlaxoSmithKline | 400 | |
| NCT00009061HIV Infections · United States | 3 | UNKNOWN | GlaxoSmithKline | 624 | |
| NCT00005106HIV Infections · United States | 4 | Completed | GlaxoSmithKline | 230 | |
| NCT00004981HIV Infections · United States | 3 | UNKNOWN | GlaxoSmithKline | 230 | |
| NCT00004852HIV Infections · United States, Argentina, Brazil and more | 2 | Completed | GlaxoSmithKline | ||
| NCT00004585HIV Infections · United States | 4 | Completed | GlaxoSmithKline | 40 | |
| NCT00004583HIV Infections · United States, Australia, Austria and more | 3 | Completed | Abbott | 660 | |
| NCT00002442HIV Infections · United States | 2 | Completed | GlaxoSmithKline | ||
| NCT00002436HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 325 | |
| NCT00002416HIV Infections · United States | 3 | Completed | triangle-pharmaceuticals | 390 | |
| NCT00002410HIV Infections · United States, Puerto Rico | 3 | Completed | Dupont Merck | ||
| NCT00002409HIV Infections · United States | 3 | Completed | GlaxoSmithKline | 200 | |
| NCT00002391HIV Infections · United States | 3 | Completed | GlaxoSmithKline | ||
| NCT00002389HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 210 | |
| NCT00002371HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | Dec 1997 | 80 |
| NCT00002320HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 320 | |
| NCT00002227HIV Infections · United States | 2 | Completed | Dupont Merck | 60 | |
| NCT00002108HIV Infections · United States | – | Completed | GlaxoSmithKline |
How it is read
Names in the registry
- “Lamivudine”, 35 entries
- “Lamivudine/Zidovudine”, 6 entries
- “Lamivudine (3TC)”, 4 entries
- “lamivudine”, 3 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 53 studies
- Acquired Immunodeficiency Syndrome, 8 studies
- Hepatitis B, Chronic, 6 studies
- Infections, 4 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.